Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGFβR2KO/IL13Rα2 CAR T-cells in Recurrent or Progressive High-Grade Glioma
NCT06815029Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Jun 2025
- Primary completion
- Oct 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TGFβR2KO/IL13Rα2 CAR T-cells in glioblastoma (GBM) and astrocytoma, sponsored by City of Hope. Primary endpoints: Dose-limiting toxicities at 28 days, Incidence of grade 3+ adverse events at 30 days and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
TGFβR2KO/IL13Rα2 CAR T-cells
03
Conditions
glioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on NCT06815029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06815029.